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DRUGS ‘R’  US
A RESPONSE TO ‘DRUG (RE) DISCOVERY:
FROM BENCH TO SPORT SIDE’
BY BEN EPSTEIN
When it said that over a third of the world’s population has little or no access to es-
sential drugs one must wonder what role the 
debate concerning a relatively small popula-
tion (consisting of professional athletes) and 
the global trend towards the commodification 
of drugs, drug-using identities and subjec-
tivities might be. I think if we start to question 
what kind of autonomous self is imagined for 
the athletes using performance-enhancing drugs 
in Ziberna’s article, and the ways in which these 
nascent drug-borne identities intersect, or are a 
confluence of, drug discovery and drug mar-
keting, we might usefully profit from an anthro-
pological and ethnographic take on the problem 
of doping in sports. I argue that the institution-
alization, management and hierarchization of 
information flows surrounding the moral panic 
of doping and pharmacology may also carry un-
wanted side effects. 
In the paper we are told that drugs, whatever 
we may think about their moral qualities, make 
our lives different. People today, presumably in 
the developed world, live longer and healthier 
lives thanks to the almost unimaginable capa-
bilities of drugs to affect almost every aspect of 
our now extended lives. Everyone from law stu-
dents to professionals can enjoy the benefits of 
‘enhanced’ mind-bodies. Only athletes are co-
opted by team managers and sponsors to break 
the rules and cheat. By enhancing their so-called 
‘normal’ physiology they can remain competi-
tive and stay on top of their game. Non-athletes 
too, it would seem, are provided with the means 
necessary to not only be healthy, but better than 
well. However, it is not just the health risk of 
doping that is at issue; it is the morally hazard-
ous body of the doped athlete that I think is also 
at stake in Ziberna’s paper. 
Participation of doctors in doping is both mor-
ally and legally against the basic principles of 
medicine, certainly, but the role of the pharma-
ceutical industry in directing what drugs should 
be prescribed in clinical settings means that 
the kind of doping which is occurring in non-
athletes is perhaps not always fair (as in cases 
involving doping students during exams using 
drugs usually marketed at people suffering from 
ADHD1 or narcolepsy). The legality of chang-
ing people’s chemistry so that they might func-
tion at their ‘fullest capacity’ is not questioned 
either, particularly in countries where over the 
counter medications are of an increased mag-
nitude in strength, or when patients can easily 
obtain such powerful medications over the In-
ternet. The difference between drugs as specific 
molecules and drugs as heavily commercialised 
items is also lacking in the discussion Ziberna 
proposes. Off-label applications of certain drugs 
can often single-handedly drive sales, and the 
extent to which drug-companies are aware of 
this is still controversial. Pharmaceutical com-
panies now market not only drugs, but also dis-
orders2.  
For drugs developed as treatments to target 
specific conditions, there may be times when 
the side effects far outweigh the benefits, but 
side effects are not always so easily identified 
as such, and may even at times be a desirable 
property of a drug. 
What’s more, it’s not that most drugs may 
cause side effects, but rather that they all inter-
act with a wide variety of body systems. The 
anti-psychotics for example may be used as 
anxiolytics, antipsychotics, antidepressants, an-
tipruritic agents, antihypertensives or antiemet-
ics. As noted psychiatrist David Healy says: ‘the 
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marketing by modern drug companies, how-
ever, actively attempts to obscure this state of 
affairs’.3 Drugs may also be ‘discovered’ long 
before any application for them has been found. 
The examples of hypertension and Viagra are 
cases in point.  
Ziberna claims that in sports the risks of dop-
ing far outweigh the benefits, but the same is 
true for many other areas where drugs are ap-
plied as magic bullets to deal with a stagger-
ing variety of conditions, not always visible as 
pathologies. Anti-depressants, for example, as 
Stefan Ecks claims in India, ‘more than other 
medicines, […] hold the promise of a quick and 
effective demarginalization’ from poverty and 
that such medicines promote the ‘message that 
seems to be: “Take this medicine and you will 
not only be happy, but married with children, 
rich, and live a Western life-style.”’4 
Medicines live social lives and this fact is 
somewhat lacking in Ziberna’s paper where 
drugs are reified as techno-scientific objects; 
amoral, apolitical, mere things; whilst the play-
ers are seen to be at ‘moral risk’ from unscru-
pulous sports agents. The drugs in and of them-
selves apparently have no moral lives to speak 
of; it is their use and misuse that ultimately 
becomes the target of the critique. But in what 
way are drugs themselves complicit in configur-
ing the moral world in which athletes find them-
selves? How do drugs come to shape the experi-
ence of doping for athletes when there are little 
alternatives to remain competitive?  And what 
degree of choice do they have caught between 
the ‘bench to sport side’ dyad as they may be?
The problem, it would seem, is that drugs 
intended for therapeutic purposes fall into the 
hands of the wrong people and eventually trick-
le down to the nebulous world of professional 
sports agents, somehow always one step ahead 
of the anti doping regulations. This, according to 
Ziberna, is because scientists are not concerned 
with the potential misapplications of drugs in 
sports, and such an oversight on the part of the 
drug companies to properly regulate the kinds 
of drugs that may have such applications, may 
have terrible consequences for the athletes who 
consume them.
The solution Ziberna proposes seems to fall 
short of the idea of doping as a health risk and a 
moral failing. To make a change to this nefari-
ous situation, raising awareness and education 
about risks associated with such drugs is per-
ceived to be encouraging but insufficient. Nip-
ping the problem in the bud by creating ‘faster 
analysis, higher sensitivity and stronger proof’ 
of drugs and their potential application to sports 
before they have been released for clinical tri-
als or in their early phases seems like a promis-
ing but costly solution. However, tackling the 
problem of situating the athletes themselves as 
agents who have to keep up with the latest per-
formance enhancing drugs by actively seeking 
them out is another matter. And the potential 
profits for drug companies to surreptitiously 
market performance enhancing drugs at athletes 
may also usefully bear reflection.  
What kind of agency and rationality we as-
cribe to the athlete’s pharmaceutical self has se-
rious implications for the way in which we can 
depict the interactions they may have with drug 
discovery.  Stereotyping athletes as either crimi-
nals/cheaters or addicts seems to downplay what 
we might call the excessive potentiality of drugs 
as socially embedded and their ability to engen-
der social consequences. Considering pharma-
cological compounds as ‘discovered’ is in some 
sense also slightly naive. Drugs are boundary 
objects and have ‘different meanings in differ-
ent social worlds but their structure is common 
enough to more than one world to make them 
recognisable’.5  Through standards, ‘abstracta-
bility and movement across diverse social and 
cultural situations, [drugs] gain a legibility and 
functionality in heterogeneous domains.’6 
The way drugs are depicted as being bounded 
but mobile objects flowing in neatly unilateral 
ways as represented in handy diagrams and typ-
ified in translational medicine simplifies what is 
in fact a very complex and messy arrangement. 
The athletes’ brain chemistry, individual histo-
ry, pharmacological action and social dynamics 
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are difficult if not impossible to disaggregate.7 
Gene-doping, for example to treat pain, may not 
immediately be considered as enhancement or 
therapeutic, but could have unintended enhanc-
ing potential when athletes can later submit to 
more intense pain for longer.8 The availability of 
drugs and their coalescence in wealthier, more 
urbane parts of the world compared to the lack 
of drugs in others, may have a serious impact on 
top athletes training in less economically pros-
perous countries. Drugs in one place, may not 
be the same drugs in another. Their ability to re-
configure our moral worlds, and engender such 
debates, highlights the importance of continued 
research in this direction. uf
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